nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

27.07.2018 | Original Article – Clinical Oncology

Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival

verfasst von: Athina Kladi-Skandali, Konstantinos Mavridis, Andreas Scorilas, Diamantis C. Sideris

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Considering the unmet need for novel molecular tumor markers capable of improving prostate cancer (CaP) patients’ management along with the fruitful results regarding the future use of ribonucleases (RNases) as molecular diagnostic and prognostic markers in CaP, we aimed to study the expressional profile of RNase κ in CaP and BPH and to investigate its clinical significance in CaP.

Methods

Total RNA was extracted from 212 prostatic tissue samples (101 BPH and 111 CaP) and, following cDNA synthesis, quantitative real-time PCR (qPCR) was performed for the expressional quantification of RNase κ. Extensive statistical analysis, including bootstrap resampling, was performed to investigate the differential expression of RNase κ in patients with BPH and CaP and its associations with patients’ clinicopathological and survival data.

Results

RNase κ was significantly downregulated (P = 0.002) in CaP patients compared to BPH ones. RNase κ overexpression was associated with decreased risk of CaP development and can discriminate between CaP and BPH independently of serum PSA levels (crude odds ratio = 0.93, P = 0.001). RNase κ upregulation was also associated with less advanced (P = 0.018) and less aggressive (P = 0.001) tumors as well as with longer progression-free survival (PFS) (P = 0.003). Finally univariate bootstrap Cox regression confirmed that RNase κ was associated with favorable prognosis (HR = 0.85, P = 0.002).

Conclusions

RNase κ is a biomarker of favorable prognosis in CaP, which is significantly associated with less advanced and aggressive disease, as well as with enhanced PFS.

Nur mit Berechtigung zugänglich

Bettoun DJ et al (2005) Interaction between the androgen receptor and RNase L mediates a cross-talk between the interferon and androgen signaling pathways. J Biol Chem 280:38898–38901. https://doi.org/10.1074/jbc.C500324200 CrossRefPubMed

Bian XJ et al (2014) Down-regulation of Dicer and Ago2 is associated with cell proliferation and apoptosis in prostate cancer. Tumour Biol 35:11571–11578. https://doi.org/10.1007/s13277-014-2462-3 CrossRefPubMed

Boccon-Gibod L et al (2004) Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 58:382–390CrossRef

Casey G et al (2002) RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32:581–583. https://doi.org/10.1038/ng1021ng1021 CrossRefPubMed

Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, Dhir R (2006) Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol 169:1812–1820. https://doi.org/10.2353/ajpath.2006.060480 CrossRefPubMedPubMedCentral

de Kok JB et al (2005) Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 85:154–159. https://doi.org/10.1038/labinvest.3700208 CrossRefPubMed

Economopoulou MA, Fragoulis EG, Sideris DC (2007) Molecular cloning and characterization of the human RNase kappa, an ortholog of Cc RNase. Nucleic Acids Res 35:6389–6398. https://doi.org/10.1093/nar/gkm718 CrossRefPubMedPubMedCentral

Eskicorapci SY, Ozkara HA, Onder E, Akdogan B, Erkan I, Ciliv G, Ozen H (2006) Serum ribonuclease activity in the diagnosis of prostate cancer in men with serum prostate-specific antigen levels between 2.5 and 20 ng/mL Clin Biochem 39:363–366. https://doi.org/10.1016/j.clinbiochem.2005.11.020 CrossRefPubMed

Filella X, Foj L (2016) Prostate cancer detection and prognosis: from prostate specific antigen (PSA) to exosomal biomarkers. Int J Mol Sci 17. https://doi.org/10.3390/ijms17111784 CrossRef

Gkratsou AS, Fragoulis EG, Sideris DC (2014) Effect of cytostatic drugs on the mRNA expression levels of ribonuclease kappa in breast and ovarian cancer cells. Anticancer Agents Med Chem 14:400–408CrossRef

Hackett BA, Yasunaga A, Panda D, Tartell MA, Hopkins KC, Hensley SE, Cherry S RNASEK is required for internalization of diverse acid-dependent viruses Proc Natl Acad Sci U S A 112:7797–7802. https://doi.org/10.1073/pnas.1424098112 CrossRef

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013 CrossRef

Karousis ED, Sideris DC (2014) A subtle alternative splicing event gives rise to a widely expressed human RNase. k isoform PLoS One 9:e96557. https://doi.org/10.1371/journal.pone.0096557PONE-D-14-07077 CrossRefPubMed

Kim WC, Lee CH (2009) The role of mammalian ribonucleases (RNases) in cancer Biochim. Biophys Acta 1796:99–. https://doi.org/10.1016/j.bbcan.2009.05.002 CrossRef

Kim YS, Hwan JD, Bae S, Bae DH, Shick WA (2010) Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. BMC Cancer 10:576. https://doi.org/10.1186/1471-2407-10-576 CrossRefPubMedPubMedCentral

Li S, Ibaragi S, Hu GF (2011) Angiogenin as a molecular target for the treatment of prostate cancer. Curr Cancer Ther Rev 7:83–90CrossRef

Li S et al (2013) Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance. Mol Cancer Res 11:1203–1214. https://doi.org/10.1158/1541-7786.MCR-13-0072 CrossRefPubMedPubMedCentral

Liang SL, Quirk D, Zhou A (2006) RNase L: its biological roles and regulation. IUBMB Life 58:508–514 https://doi.org/10.1080/15216540600838232 CrossRefPubMed

Martinez-Fierro ML et al (2010) Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer 10:326. https://doi.org/10.1186/1471-2407-10-326 CrossRefPubMedPubMedCentral

Pascale M, Pracella D, Barbazza R, Marongiu B, Roggero E, Bonin S, Stanta G (2013) Is human papillomavirus associated with prostate cancer survival? Dis Markers 35:607–613. https://doi.org/10.1155/2013/735843 CrossRefPubMedPubMedCentral

Perreira JM et al (2015) RNASEK Is a V-ATPase-associated factor required for endocytosis and the replication of rhinovirus, influenza a virus, and dengue. Virus Cell Rep 12:850–863. https://doi.org/10.1016/j.celrep.2015.06.076 CrossRefPubMed

Rampias TN, Fragoulis EG, Sideris DC (2008) Genomic structure and expression analysis of the RNase kappa family ortholog gene in the insect ceratitis capitata. FEBS J 275:6217–6227. https://doi.org/10.1111/j.1742-4658.2008.06746.x CrossRefPubMed

Sfanos KS, De Marzo AM (2012) Prostate cancer and inflammation:. the evidence. Histopathology 60:199–215. https://doi.org/10.1111/j.1365-2559.2011.04033.x CrossRefPubMedPubMedCentral

Shlyakhovenko VO (2016) Ribonucleases. Possible new approach in cancer therapy. Exp Oncol 38:2–8PubMed

Vanli N, Guo-Fu HU (2015) Mechanism and function of angiogenin. in Prostate Cancer 31:1261–1266. https://doi.org/10.13865/j.cnki.cjbmb.2015.12.06 CrossRef

Xiang Y et al (2003) Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′,5′-oligoadenylates. Cancer Res 63:6795–6801PubMed

Zhang B et al (2014) A dosage-dependent pleiotropic role of Dicer in prostate cancer growth. and metastasis. Oncogene 33:3099–3108. https://doi.org/10.1038/onc.2013.281 CrossRefPubMed

Titel: Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival
verfasst von: Athina Kladi-Skandali
Konstantinos Mavridis
Andreas Scorilas
Diamantis C. Sideris
Publikationsdatum: 27.07.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2719-0

Springer Medizin

Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival